Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP C Frank Bennett sold 12,250 shares of the company’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $796,250.00. Following the sale, the senior vice president now owns 27,291 shares of the company’s stock, valued at approximately $1,773,915. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

C Frank Bennett also recently made the following trade(s):

  • On Monday, July 24th, C Frank Bennett sold 10,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $59.29, for a total transaction of $592,900.00.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded up 1.15% during midday trading on Friday, reaching $64.39. 1,631,810 shares of the company’s stock traded hands. The stock has a 50 day moving average of $56.15 and a 200-day moving average of $50.31. Ionis Pharmaceuticals, Inc. has a 12 month low of $24.58 and a 12 month high of $65.51. The stock has a market cap of $8.01 billion, a P/E ratio of 309.57 and a beta of 3.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.47) earnings per share. On average, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.16) EPS for the current fiscal year.

WARNING: “Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $796,250.00 in Stock” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2017/10/20/ionis-pharmaceuticals-inc-ions-svp-sells-796250-00-in-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Intl Fcstone Inc. acquired a new position in shares of Ionis Pharmaceuticals during the second quarter valued at about $598,000. WFG Advisors LP boosted its holdings in Ionis Pharmaceuticals by 77.2% during the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after purchasing an additional 1,655 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $381,000. Verition Fund Management LLC purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $742,000. Finally, Bank of Nova Scotia purchased a new position in Ionis Pharmaceuticals during the second quarter worth about $1,526,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Several brokerages have commented on IONS. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Tuesday. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 target price for the company in a research report on Tuesday. Stifel Nicolaus reiterated a “hold” rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $30.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $69.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Ionis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $50.04.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.